Indianapolis, IN3 Active Studies

Myasthenia Gravis Clinical Trials in Indianapolis, IN

Find 3 actively recruiting myasthenia gravis clinical trials in Indianapolis, IN. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
325
Enrolling

Recruiting Myasthenia Gravis Studies in Indianapolis

About Myasthenia Gravis Clinical Trials in Indianapolis

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles responsible for breathing and movement. It occurs when communication between nerves and muscles is disrupted. Treatment includes medications that improve neuromuscular transmission and immunosuppressive therapies.

There are currently 3 myasthenia gravis clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 325 participants. Research is being sponsored by Ad scientiam, Janssen Research & Development, LLC, Kyverna Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myasthenia Gravis Clinical Trials in Indianapolis — FAQ

Are there myasthenia gravis clinical trials in Indianapolis?

Yes, there are 3 myasthenia gravis clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Indianapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.

Are clinical trials in Indianapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.

What myasthenia gravis treatments are being tested?

The 3 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for myasthenia gravis.

Data updated October 13, 2026 from ClinicalTrials.gov